Abstract:En-Yi Lin, 1, 2 Shao-Xi Hsu, 1 Bing-Hua Wu, 1 Yu-Chen Deng, 1, 3 Wei Wuli, 1 Yuan-Sheng Li, 3 Jui-Hao Lee, 3 Shinn-Zong Lin, 2, 4 Horng-Jyh Harn, 2, 5 Tzyy-Wen Chiou 1 1 Department of Life Science and Graduate Institute of Biotechnology, National Dong Hwa University, Hualien, Taiwan; 2 Bioinnovation Center, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan; 3 Everfront Biotech Inc, Taipei, Taiwan; 4 Department of Neurosurgery, Hualien Tzu Chi Hospital, Hualien, Taiwan; 5 Department of Pathology, Hualien Tzu Chi Hospital, Hualien, Taiwan Correspondence: Tzyy-Wen Chiou, Department of Life Science, National Dong Hwa University, No. 1, Sec. 2, Da Hsueh Road, Shou-Feng, Hualien, Taiwan, Tel +886-3-890-3638, Email Horng-Jyh Harn, Department of Pathology, Hualien Tzu Chi Hospital, Hualien, Taiwan, Tel +886-3-856-1825, Email Purpose: Exosomes are membrane vesicles secreted by various cells and play a crucial role in intercellular communication. They can be excellent delivery vehicles for oligonucleotide drugs, such as microRNAs, due to their high biocompatibility. MicroRNAs have been shown to be more stable when incorporated into exosomes; however, the lack of targeting and immune evasion is still the obstacle to the use of these microRNA-containing nanocarriers in clinical settings. Our goal was to produce functional exosomes loaded with target ligands, immune evasion ligand, and oligonucleotide drug through genetic engineering in order to achieve more precise medical effects. Methods: To address the problem, we designed engineered exosomes with exogenous cholecystokinin (CCK) or somatostatin (SST) as the targeting ligand to direct the exosomes to the brain, as well as transduced CD47 proteins to reduce the elimination or phagocytosis of the targeted exosomes. MicroRNA-29b-2 was the tested oligonucleotide drug for delivery because our previous research showed that this type of microRNA was capable of reducing presenilin 1 (PSEN1) gene expression and decreasing the β-amyloid accumulation for Alzheimer's disease (AD) in vitro and in vivo. Results: The engineered exosomes, containing miR29b-2 and expressing SST and CD47, were produced by gene-modified dendritic cells and used in the subsequent experiments. In comparison with CD47-CCK exosomes, CD47-SST exosomes showed a more significant increase in delivery efficiency. In addition, CD47-SST exosomes led to a higher delivery level of exosomes to the brains of nude mice when administered intravenously. Moreover, it was found that the miR29b-2-loaded CD47-SST exosomes could effectively reduce PSEN1 in translational levels, which resulted in an inhibition of beta-amyloid oligomers production both in the cell model and in the 3xTg-AD animal model. Conclusion: Our results demonstrated the feasibility of the designed engineered exosomes. The application of this exosomal nanocarrier platform can be extended to the delivery of other oligonucleotide drugs to specific tissues for the treatment of diseases while evading the immune system. Keywords: oligonucleotide drug, functional nanocarriers, hippocampus, SH-SY5Y, 3xTG-AD In accordance with a report issued by the World Health Organization, 1 there are 55 million people worldwide who suffer from dementia, of which 60–70% have AD. In spite of the growing number of patients with AD, there is still no effective drug for its clinical treatment. Therefore, it is urgent to develop new therapeutic strategies that can effectively delay the progression of the disease, alleviate the symptoms, and enhance cognitive function. Our previous study demonstrated that by increasing miRNA-29b-2-5p expression, the PSEN-1 gene could be targeted and inhibited, thus reducing the activity of γ-secretase and reducing amyloid production. 2 In light of this, we consider miRNA-29b-2-5p has the potential to be developed into a new anti-Alzheimer's oligonucleotide drug. There are two types of AD: early-onset AD (also known as familial AD) and late-onset AD (also known as sporadic AD). 3 In general, early-onset AD accounts for only 5% of all cases of AD. Its cause, however, is primarily related to gene mutations. An abnormal presenilin 1 (PSEN1) is produced by the presenilin 1 gene mutation present on the 14th pair of chromosomes. As the most common AD gene mutation, PSEN1 accounts for roughly 50% of early-onset disease-causing genes. 4,5 Mutations in PSEN1 that carry only a single allele increase the risk of developing late-onset AD. 6 PSEN1 is one of the components of γ-secretase. One of the strategies for developing drugs to trea -Abstract Truncated-

Down-regulation Amyloid Beta-Protein 42 Production by Interfering with Transcript of Presenilin 1 Gene with Sirna.

[Effects of RNA Interference Targeting P2X7 Receptor on Microglial Phagocytosis of Amyloid-Β Protein].

Mutation Analysis of Presenilin-1 Gene in Alzheimer' S Disease Patients and the Effects of Its Mutation on Expression of Presenilin-1 and Amyloid Precursor Protein

Small interference RNA inhibits the endogenous expression of beta-site APP cleaving enzyme-1 protein in neuro-2a cells

Engineered Exosomes Containing microRNA-29b-2 and Targeting the Somatostatin Receptor Reduce Presenilin 1 Expression and Decrease the β-Amyloid Accumulation in the Brains of Mice with Alzheimer's Disease

miR-3940-5p reduces amyloid β production via selectively targeting PSEN1

RNA interference silencing P2X7 receptor restrained inflammatory factors released from the microglia

Peptides of presenilin-1 bind the amyloid precursor protein ectodomain and offer a novel and specific therapeutic approach to reduce ß-amyloid in Alzheimer's disease

Targeting Β-Secretase with RNAi in Neural Stem Cells for Alzheimer's Disease Therapy.

Dicer1 promotes Aβ clearance via blocking B2 RNA-mediated repression of apolipoprotein E

Induction of Silencing Effect of Swedish Mutant Amyloid Precursor Protein by RNA Interference

A Dual Targeting Drug Delivery System for Penetrating Blood-Brain Barrier and Selectively Delivering Sirna to Neurons for Alzheimer's Disease Treatment.

Targeting PSEN1 by lnc-CYP3A43-2/miR-29b-2-5p to Reduce β Amyloid Plaque Formation and Improve Cognition Function

Down‐regulation of Insulin‐degrading Enzyme by Presenilin 1 V97L Mutant Potentially Underlies Increased Levels of Amyloid Beta 42

Inhibition of Γ-Secretase Activity Reduces Aβ Production, Reduces Oxidative Stress, Increases Mitochondrial Activity and Leads to Reduced Vulnerability to Apoptosis: Implications for the Treatment of Alzheimer's Disease

Small Interfering RNA Delivery to the Neurons Near the Amyloid Plaques for Improved Treatment of Alzheimer׳s Disease

The Effect of BACE1-AS on Β-Amyloid Generation by Regulating BACE1 Mrna Expression

Induction of silencing effect of Alzheimer disease familial Swedish mutant APP by RNA interference

Transcriptional regulation of the presenilin-1 gene controls gamma-secretase activity

Construction of Drug Screening Cell Model and Application to New Compounds Interfering Production and Accumulation of Beta-Amyloid by Inhibiting Gamma-Secretase

Profiling of Differential Expression of Genes in Mice Carrying Both Mutant Presenilin 1 and Amyloid Precursor Protein Transgenes with or Without Knockout of Β2 Adrenergic Receptor Gene